Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1939 1
1940 1
1949 1
1950 1
1951 1
1952 1
1953 1
1955 1
1956 2
1957 2
1958 2
1959 4
1960 2
1961 4
1962 1
1963 5
1964 3
1965 4
1966 3
1967 5
1968 1
1969 4
1970 10
1971 5
1972 6
1973 8
1974 7
1975 5
1976 6
1977 8
1978 7
1979 5
1980 7
1981 4
1982 7
1983 12
1984 5
1985 5
1986 10
1987 8
1988 12
1989 6
1990 9
1991 6
1992 10
1993 12
1994 12
1995 16
1996 9
1997 10
1998 8
1999 9
2000 9
2001 6
2002 8
2003 10
2004 4
2005 7
2006 9
2007 10
2008 4
2009 7
2010 6
2011 8
2012 5
2013 6
2014 8
2015 9
2016 12
2017 10
2018 7
2019 12
2020 13
2021 11
2022 19
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

484 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT, Wingo TS, Hales CM, Gámez Tansey M, Goldstein DS, Abrol A, Calhoun VD, Goldstein FC, Hajjar I, Fagan AM, Galasko D, Edland SD, Hanfelt J, Lah JJ, Weinshenker D. Levey AI, et al. Among authors: goldstein fc. Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452. Brain. 2022. PMID: 34919634 Free PMC article. Clinical Trial.
Adjuncts to opioid therapy.
Goldstein FJ. Goldstein FJ. J Am Osteopath Assoc. 2002 Sep;102(9 Suppl 3):S15-21. J Am Osteopath Assoc. 2002. PMID: 12356036 Review.
Progress in pain management: where are we?
Goldstein FJ. Goldstein FJ. J Opioid Manag. 2005 Mar-Apr;1(1):9-10. doi: 10.5055/jom.2005.0004. J Opioid Manag. 2005. PMID: 17315404 No abstract available.
The epidemiology of bacterial resistance to quinolones.
Acar JF, O'Brien TF, Goldstein FW, Jones RN. Acar JF, et al. Among authors: goldstein fw. Drugs. 1993;45 Suppl 3:24-8. doi: 10.2165/00003495-199300453-00006. Drugs. 1993. PMID: 7689447 Review.
Mild antecedent COVID-19 associated with symptom-specific post-acute sequelae.
Walker TA, Truong AD, Summers A, Dixit AN, Goldstein FC, Hajjar I, Echols MR, Woodruff MC, Lee ED, Tekwani S, Carroll K, Sanz I, Lee FE, Han JE. Walker TA, et al. Among authors: goldstein fc. PLoS One. 2023 Jul 10;18(7):e0288391. doi: 10.1371/journal.pone.0288391. eCollection 2023. PLoS One. 2023. PMID: 37428786 Free PMC article.
484 results